Wednesday, February 1, 2023
Google search engine
HomeMarketResultsSTAAR Surgical (NASDAQ:STAA) PT Lowered to $67.00

STAAR Surgical (NASDAQ:STAA) PT Lowered to $67.00


STAAR Surgical (NASDAQ:STAAGet Rating) had its goal value lower by BTIG Analysis from $80.00 to $67.00 in a analysis observe issued on Wednesday, The Fly studies. BTIG Analysis’s goal value would point out a possible upside of 39.64% from the corporate’s present value.

STAA has been the topic of various different studies. Canaccord Genuity Group lowered their value goal on shares of STAAR Surgical from $88.00 to $79.00 and set a “purchase” score for the corporate in a analysis observe on Wednesday, November thirtieth. Canaccord Genuity Group dropped their goal value on shares of STAAR Surgical from $97.00 to $88.00 and set a “purchase” score on the inventory in a report on Friday, October 14th. Needham & Firm LLC dropped their goal value on shares of STAAR Surgical from $110.00 to $83.00 and set a “purchase” score on the inventory in a report on Thursday, November third. Sidoti raised shares of STAAR Surgical from a “impartial” score to a “purchase” score in a report on Monday, November seventh. Lastly, Mizuho initiated protection on shares of STAAR Surgical in a report on Wednesday, October twelfth. They issued a “purchase” score and a $85.00 goal value on the inventory. Two funding analysts have rated the inventory with a maintain score and 9 have issued a purchase score to the corporate. Primarily based on knowledge from MarketBeat, the corporate has a consensus score of “Average Purchase” and a median value goal of $87.70.

STAAR Surgical Buying and selling Down 0.8 %

Shares of NASDAQ STAA opened at $47.98 on Wednesday. The agency has a market cap of $2.31 billion, a PE ratio of 63.13 and a beta of 1.00. STAAR Surgical has a 1-year low of $46.38 and a 1-year excessive of $112.27. The corporate has a fifty day shifting common value of $61.17 and a 200 day shifting common value of $74.00.

STAAR Surgical (NASDAQ:STAAGet Rating) final introduced its earnings outcomes on Wednesday, November 2nd. The medical devices provider reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.12. The agency had income of $76.05 million in the course of the quarter, in comparison with analyst estimates of $74.95 million. STAAR Surgical had a internet margin of 13.54% and a return on fairness of 15.13%. The corporate’s income for the quarter was up 30.3% in comparison with the identical quarter final 12 months. Throughout the identical interval within the prior 12 months, the enterprise earned $0.13 EPS. Equities analysis analysts forecast that STAAR Surgical will publish 0.84 EPS for the present 12 months.

Institutional Inflows and Outflows

Institutional buyers and hedge funds have not too long ago made modifications to their positions within the enterprise. Arizona State Retirement System grew its place in shares of STAAR Surgical by 6.9% in the course of the 2nd quarter. Arizona State Retirement System now owns 11,000 shares of the medical devices provider’s inventory price $780,000 after buying a further 706 shares within the final quarter. Royce & Associates LP grew its place in shares of STAAR Surgical by 3.6% in the course of the 2nd quarter. Royce & Associates LP now owns 57,984 shares of the medical devices provider’s inventory price $4,113,000 after buying a further 2,039 shares within the final quarter. Nicholas Firm Inc. grew its place in shares of STAAR Surgical by 66.2% in the course of the 2nd quarter. Nicholas Firm Inc. now owns 105,025 shares of the medical devices provider’s inventory price $7,449,000 after buying a further 41,850 shares within the final quarter. Point72 Asset Administration L.P. acquired a brand new stake in shares of STAAR Surgical in the course of the 2nd quarter price roughly $3,334,000. Lastly, Los Angeles Capital Administration LLC boosted its place in shares of STAAR Surgical by 1.1% in the course of the 2nd quarter. Los Angeles Capital Administration LLC now owns 61,268 shares of the medical devices provider’s inventory price $4,346,000 after buying a further 649 shares within the final quarter. Institutional buyers and hedge funds personal 97.55% of the corporate’s inventory.

STAAR Surgical Firm Profile

(Get Rating)

STAAR Surgical Firm, along with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the attention, and companion supply techniques to ship the lenses into the attention. The corporate gives Visian implantable Collamer lens product household (ICLs) to deal with visible issues, corresponding to myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Tales

The Fly logo

Analyst Recommendations for STAAR Surgical (NASDAQ:STAA)

This instantaneous information alert was generated by narrative science know-how and monetary knowledge from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account STAAR Surgical, you may need to hear this.

MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and STAAR Surgical wasn’t on the checklist.

Whereas STAAR Surgical at present has a “Average Purchase” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments